Breathe Well Live Well
|
KaloBios commences KB003 Phase 2 trial in severe asthma
News-Medical.net KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma … |
View full post on asthma – Google News
|
Rigel commences two Phase II allergic asthma and DLE studies
Equities.com Approximately 270 adults with allergic asthma will be randomized into the three arms of this Phase II clinical study of R343, called SITAR, or SYK Inhibition for Treatment of Asthma with R343, for eight weeks of treatment with either of two different … |
View full post on asthma – Google News
|
Phase II Trial of ASM8 in Asthma Commences
irasia.com (press release) Pharmaceutical company Pharmaxis (ASX: PXS) today announced it had enrolled the first subjects into a Phase II clinical trial evaluating the new asthma drug … |
View full post on asthma – Google News